Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTBP2 | P56545 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29635163 | 0.83 | CTBP2 (0.61) | CTBP2POLBL3MBTL1NPC1TAAR1 | |
| SCHEMBL7073775 | 0.83 | CTBP2 (0.61) | CTBP2POLBL3MBTL1NPC1TAAR1 | |
| SCHEMBL504093 | 0.82 | CTBP2 (0.64) | CTBP2POLBL3MBTL1NPC1TAAR1 | |
| SCHEMBL29407189 | 0.82 | CTBP2 (0.64) | CTBP2POLBL3MBTL1NPC1TAAR1 | |
| SCHEMBL2532630 | 0.82 | CTBP2 (0.64) | CTBP2POLBL3MBTL1NPC1TAAR1 | |
| SCHEMBL1259064 | 0.82 | CTBP2 (0.59) | CTBP2POLBL3MBTL1NPC1TAAR1 | |
| SCHEMBL1699683 | 0.82 | CTBP2 (0.59) | CTBP2POLBL3MBTL1NPC1TAAR1 | |
| SCHEMBL24458263 | 0.80 | CTBP2 (0.57) | CTBP2POLBL3MBTL1NPC1TAAR1 | |
| SCHEMBL726784 | 0.80 | CTBP2 (0.57) | CTBP2POLBL3MBTL1NPC1TAAR1 | |
| Ammonia Solution, Strong SCHEMBL22042028 | 0.80 | CTBP2 (0.62) | CTBP2POLBL3MBTL1NPC1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| WO-2004018428-A1 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| EP-1902717-A2 | Vasopressin antagonist and oxytocin antagonist | Otsuka Pharmaceutical Company, Limited (JP) | 2008-03-26 | — | — | EP | disclosed |
| EP-0620003-B1 | VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST | OTSUKA PHARMA CO LTD (JP) | 2008-01-16 | — | — | EP | disclosed |
| EP-1085009-B1 | INDAN DERIVATIVES | NISSAN CHEMICAL IND LTD (JP) | 2004-11-10 | — | — | EP | disclosed |
| EP-0934296-B1 | CHROMAN DERIVATIVES | NISSAN CHEMICAL IND LTD (JP) | 2003-06-04 | — | — | EP | disclosed |
| US-6486178-B1 | Indane derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-26 | — | — | US | disclosed |
| EP-1085009-A1 | INDAN DERIVATIVES | Nissan Chemical Industries, Ltd. (JP) | 2001-03-21 | — | — | EP | disclosed |
| EP-0765879-B1 | 13-Substituted milbemycin 5-oxime derivatives, their preparation and their use against insects and other pests | SANKYO CO (JP) | 2001-02-14 | — | — | EP | disclosed |
| US-6066631-A | Chroman derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-05-23 | — | — | US | disclosed |
| US-4301280-A | Preparation of 3-substituted cephalosporins | LILLY INDUSTRIES LIMITED (GB) | 1981-11-17 | — | — | US | disclosed |
| US-4176231-A | Process for preparing 3-exomethylenecepham sulfoxides | LILLY INDUSTRIES LIMITED (GB) | 1979-11-27 | — | — | US | disclosed |
| US-4159266-A | AZETIDINONE SULFINIC ACID DERIVATIVES | ELI LILLY AND COMPANY (US) | 1979-06-26 | — | — | US | disclosed |
| US-4052387-A | METHOD OF PREPARATION OF 3-METHYLENECEPHAMS | ELI LILLY AND COMPANY (US) | 1977-10-04 | — | — | US | disclosed |
| US-4048163-A | Process for preparation of 7-alkoxy-3-chloromethylcephems | ELI LILLY AND COMPANY (US) | 1977-09-13 | — | — | US | disclosed |
| US-4048160-A | Process for preparation of 7-alkoxy-3-bromomethylcephems | ELI LILLY AND COMPANY (US) | 1977-09-13 | — | — | US | disclosed |
| US-4042585-A | Process for preparation of 3-halomethylcephems | ELI LILLY AND COMPANY (US) | 1977-08-16 | — | — | US | disclosed |
| US-4038275-A | PROCESS FOR PREPARATION OF 3-HYDROXYMETHYLCEPHEMS | ELI LILLY AND COMPANY (US) | 1977-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | CTBP2 956/4885POLB 626/4885L3MBTL1 2013/4885 |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | CTBP2 1195/4885POLB 637/4885L3MBTL1 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.